Magnetic Resonance Imaging Study of Geriatric Depression

Mclean Hospital43 enrolled

Overview

The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression. We hypothesized that concentrations of high energy metabolites would be lower in depressed elderly compared to non-depressed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Major Depressive Disorder

Interventions

SertralineDRUG

Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day. Duration of treatment was 12 weeks.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 89 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * DSM- IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) diagnostic criteria for major depressive disorder * Hamilton Depression Scale- 17 item version score of 18 or higher * Must speak English * Women must be post-menopausal Exclusion Criteria: * A current or pervious psychiatric disorder other than MDD * A current unstable medical condition * A pacemaker or metal implant * History of alcohol or drug dependence or abuse within the past year * Current prescription of excluded medications * Use of a drug within the last 30 days that was not approved for use by governmental authorities. * If you or a family member works at McLean Hospital

Locations (1)

McLean Hospital

Belmont, Massachusetts, United States

Outcomes

Primary Outcomes

HAM-D 17 (Hamilton Depression Rating Scale)

This is a depression severity rating scale measuring symptoms of depression including mood, sleep, appetite, energy, motivation, guilt, suicidal ideation, concentration, physical complaints, paranoia, anxiety, effect on daily functioning and awareness of illness. Scale is from 0 (no depression symptoms) up to a maximum of 66 (severe depression symptoms).

Time frame: baseline at study entry week 0

Geriatric Depression Scale

This is a depression severity rating scale measuring symptoms of depression. Scale is from 0 (no depression symptoms) up to a maximum of 15 (severe depression symptoms).

Time frame: baseline at study entry week 0

Phosphorus Magnetic Resonance Spectroscopy (31P-MRS)

The primary outcome is a phosphorus magnetic resonance spectroscopy (31P-MRS) signal quantified using a spectral time-domain fitting program based on the Marquadt-Levenberg non-linear, least-squares algorithm, that incorporates prior knowledge of spectral peak assignments, chemical shifts and J-coupling constants. Least squares means were calculated for average total signal using linear mixed effects models. Results are expressed as a spectroscopic index. beta-nucleoside triphosphate (bNTP) Phosphocreatine (PCr) Total nucleoside triphosphate (NTP)

Time frame: at week 0 for both control and depressed, and at week 12 for depressed

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.